Cytosorbents Corporation (CTSO)

Market Cap	50.08M
Revenue (ttm)	37.74M
Net Income (ttm)	-18.67M
Shares Out	54.68M
EPS (ttm)	-0.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,217
Open	0.930
Previous Close	0.960
Day's Range	0.910 - 0.965
52-Week Range	0.700 - 2.150
Beta	0.56
Analysts	Strong Buy
Price Target	4.67 (+409.88%)
Earnings Date	Nov 7, 2024

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 186
• Stock Exchange: NASDAQ
• Ticker Symbol: CTSO
• Website: https://www.cytosorbents.com

Financial Performance

In 2023, Cytosorbents's revenue was $36.35 million, an increase of 4.79% compared to the previous year's $34.69 million. Losses were -$28.51 million, -13.12% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for CTSO stock is "Strong Buy." The 12-month stock price forecast is $4.67, which is an increase of 409.88% from the latest price.

Price Target

$4.67

(409.88% upside)

Analyst Consensus: Strong Buy